Skip to main content
GRFS
NASDAQ Life Sciences

Grifols Doses First Patients in Two Phase 3 Trials for Immunoglobulin Label Expansion

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$7.03
Mkt Cap
$6.217B
52W Low
$6.96
52W High
$11.14
52W Position info
1.0% above low
Off High info
37% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

GRFS is trading near its 52-week low of $6.96 (1.0% above the low).

Summary

Grifols has dosed the first patients in two Phase 3 trials aiming to expand U.S. labels for its key immunoglobulin products, GAMUNEX-C and XEMBIFY. The SIGMA trial targets secondary immunodeficiency in blood cancer patients, a market of over 1 million U.S. patients, while XPERT tests XEMBIFY against GAMUNEX-C in CIDP, a 60,000-patient indication. These trials build on the strong commercial momentum of the Ig portfolio, with XEMBIFY growing nearly 60% in 2025. Positive results could unlock significant new revenue streams and reinforce the company's turnaround narrative following recent debt refinancing and credit upgrades. The stock trades near its 52-week low, so pipeline progress may draw attention to undervalued growth prospects.

At the time of this announcement, GRFS was trading at $7.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $6.96 to $11.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

GRFS - Latest Insights

GRFS
Nov 02, 2026, 11:54 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $8.48
Real-time Price: $8.47 info
Change: -$0.0050 (-0.06%) info
Market Cap: $7.485B info
GRFS
Jul 28, 2026, 5:41 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $8.33
Real-time Price: $8.47 info
Change: +$0.140 (+2%) info
Market Cap: $7.485B info
GRFS
Jun 18, 2026, 4:00 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $7.40
Real-time Price: $8.47 info
Change: +$1.07 (+14%) info
Market Cap: $7.485B info
GRFS
May 15, 2026, 1:13 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $7.61
Real-time Price: $8.47 info
Change: +$0.860 (+11%) info
Market Cap: $7.485B info
GRFS
May 07, 2026, 2:35 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $8.16
Real-time Price: $8.47 info
Change: +$0.315 (+4%) info
Market Cap: $7.485B info